# **Advanced DID**

#### MULTIPLE PERIODS + STAGGERED TREATMENT TIMING



# Staggered Timing

- Remember that in the canonical DiD model we had:
	- $\rightarrow$  Two periods and a common treatment date
	- $\rightarrow$  Identification from parallel trends and no anticipation
	- $\rightarrow$  A large number of clusters for inference
- A very active recent literature has focused on relaxing the first assumption: **what if there are multiple periods and units adopt treatment at different times?**
- This literature typically maintains the remaining ingredients: parallel trends and many clusters

# Overview of Staggered Timing Literature

- 1. Negative results: TWFE OLS doesn't give us what we want with treatment effect heterogeneity
- 2. New estimators: perform better under treatment effect heterogeneity
- Panel of observations for periods  $t = 1, ..., T$
- Suppose units adopt a binary treatment at different dates  $G_i \in \{1, ..., T\} \cup \infty$ (where  $G_i = \infty$  means "never-treated")
	- $\rightarrow$  Active literature considering cases with continuous treatment & treatments that turn on/off (see Section 3.4 of review paper)
- Potential outcomes  $Y_{it}(q)$  depend on time and time you were first-treated

# Extending the Identifying Assumptions

- The key identifying assumptions from the canonical model are extended in the natural way
- **Parallel trends:** Intuitively, says that if treatment hadn't happened, all "adoption cohorts" would have parallel average outcomes in all periods

$$
E[Y_{it}(\infty) - Y_{i,t-1}(\infty)|G_i = g] = E[Y_{it}(\infty) - Y_{i,t-1}(\infty)|G_i = g'] \text{ for all } g, g', t
$$

Note: can impose slightly weaker versions (e.g. only require PT post-treatment)

• **No anticipation:** Intuitively, says that treatment has no impact before it is implemented

$$
Y_{it}(g) = Y_{it}(\infty)
$$
 for all  $t < g$ 

#### Negative results

• Suppose we again run the regression

$$
Y_{it} = \alpha_i + \phi_t + D_{it}\beta + \epsilon_{it},
$$

where  $D_{it} = 1[t \ge G_i]$  is a treatment indicator.

• Suppose we're willing to assume no anticipation and parallel trends across all adoption cohorts as described above

#### Negative results

• Suppose we again run the regression

 $Y_{it} = \alpha_i + \phi_t + D_{it}\beta + \epsilon_{it}$ 

where  $D_{it} = 1[t \ge G_i]$  is a treatment indicator.

- Suppose we're willing to assume no anticipation and parallel trends across all adoption cohorts as described above
- Good news: If each unit has a constant treatment effect over time,  $Y_{it}(q) Y_{it}(\infty) \equiv \tau_i$ , get a weighted avg of  $\tau_i$

#### Negative results

• Suppose we again run the regression

 $Y_{it} = \alpha_i + \phi_t + D_{it}\beta + \epsilon_{it}$ 

where  $D_{it} = 1[t \ge G_i]$  is a treatment indicator.

- Suppose we're willing to assume no anticipation and parallel trends across all adoption cohorts as described above
- Good news: If each unit has a constant treatment effect over time,  $Y_{it}(q) Y_{it}(\infty) \equiv \tau_i$ , get a weighted avg of  $\tau_i$
- Bad news: if treatment effects are heterogeneous (within unit over time), then  $\beta$  may put negative weights on treatment effects for some units and time periods
	- $\rightarrow$  E.g., if treatment effect depends on time since treatment,  $Y_{it}(t-r) Y_{it}(\infty) = \tau_r$ , then some  $\tau_r$ s may get negative weight

# Where do these negative results come from?

- The intuition for these negative results is that the TWFE OLS specification combines two sources of comparisons:
	- 1. **Clean comparisons:** DiD's between treated and not-yet-treated units
	- 2. **Forbidden comparisons:** DiD's between newly-treated and already-treated units
- These forbidden comparisons can lead to negative weights: the "control group" is already treated, so we run into problems if their treatment effects change over time

#### Some intuition for forbidden comparisons

- Consider the two period model, except suppose now that our two groups are **always-treated** units (treated in both periods) and **switchers** (treated only in period 2)
- With two periods, the coefficient  $\beta$  from  $Y_{it} = \alpha_i + \phi_t + D_{it}\beta + \epsilon_{it}$  is the same as from the first-differenced regression  $\Delta Y_i = \alpha + \Delta D_i \beta + u_i$
- $\bullet\,$  Observe that  $\Delta D_i$  is one for switchers and zero for stayers. That is, the stayers function as the "control group"! Thus,

$$
\hat{\beta} = \underbrace{(\bar{Y}_{Switchers,2} - \bar{Y}_{Switchers,1})}_{\text{Change for switches}} - \underbrace{(\bar{Y}_{AT,2} - \bar{Y}_{AT,1})}_{\text{Change for always treated}}
$$

- Problem: if the effect for the always-treated grows over time, that will enter  $\hat{\beta}$  negatively!
- With staggered timing, units who are treated early are like "always-treated" in later pairs of  $periods$  8/20

#### Second Intuition for Negative Weights

- The Frisch-Waugh-Lovell theorem says that we can obtain the coefficient  $\beta$  in  $Y_{it} = \alpha_i + \phi_t + D_{it}\beta + \epsilon_{it}$  by the following two-step procedure.
- First, regress the treatment indicator  $D_{it}$  on the FEs (a linear probability model):  $D_{it} = \tilde{\alpha}_i + \tilde{\phi}_t + \tilde{\epsilon}_{it}$
- Then run a univariate regression of  $Y_{it}$  on  $D_{it} \hat{D}_{it}$  to obtain  $\beta$ .

$$
\rightarrow \text{Thus, } \beta = \frac{Cov(Y_{it}, D_{it} - \hat{D}_{it})}{Var(D_{it} - \hat{D}_{it})} = \frac{E(Y_{it}(D_{it} - \hat{D}_{it}))}{Var(D_{it} - \hat{D}_{it})}
$$

However, it's well known that the linear probability model for  $D_{it}$  may have predictions outside the unit interval. If  $\hat{D}_{it} > 1$  even though unit  $i$  is treated in period  $t$ , then  $D_{it} - \hat{D}_{it} < 0$ , and thus  $Y_{it}$  gets negative weight.

# Not just negative but weird...

The literature has placed a lot of emphasis on the fact that some treatment effects may get negative weights

- But even if the weights are non-negative, they might not give us the most intuitive parameter
- For example, suppose each unit  $i$  has treatment effect  $\tau_i$  in every period if they are treated (no dynamics). Then  $\beta$  gives a weighted average of the  $\tau_i$  where the weights are largest for units treated closest to the middle of the panel
- It is not obvious that these weights are relevant for policy, even if they are all non-negative!

# Issues with dynamic TWFE

• [Sun and Abraham \(2021\)](#page-36-0) show that similar issues arise with dynamic TWFE specifications:

$$
Y_{i,t} = \alpha_i + \lambda_t + \sum_{k \neq 0} \gamma_k D_{i,t}^k + \varepsilon_{i,t},
$$

where  $D_{i,t}^k = 1$   $\{ t - G_i = k \}$  are "event-time" dummies.

- Like for the static spec,  $\gamma_k$  may be a non-convex weighted average of the dynamic treatment effect  $k$  periods after treatment
- SA also show that  $\gamma_k$  may be "contaminated" by treatment effects at lags  $k'\neq k$

# Dynamic TWFE - Continued

- The results in SA suggest that interpreting the  $\hat{\gamma}_k$  for  $k = 1, 2, ...$  as estimates of the dynamic effects of treatment may be misleading
- These results also imply that pre-trends tests of the  $\gamma_k$  for  $k < 0$  may be misleading  $$ could be non-zero even if parallel trends holds, since they may be "contaminated" by post-treatment effects!

# Dynamic TWFE - Continued

- The results in SA suggest that interpreting the  $\hat{\gamma}_k$  for  $k = 1, 2, ...$  as estimates of the dynamic effects of treatment may be misleading
- These results also imply that pre-trends tests of the  $\gamma_k$  for  $k < 0$  may be misleading  $$ could be non-zero even if parallel trends holds, since they may be "contaminated" by post-treatment effects!
- The issues discussed in SA arise if dynamic path of treatment effects is heterogeneous across adoption cohorts
	- $\rightarrow$  Biases may be less severe than for "static" specs if dynamic patterns are similar across cohorts

# New estimators (and estimands!)

- Several new (closely-related) estimators have been proposed to try to address these negative weighting issues
- The key components of all of these are:
	- Be precise about the target parameter (estimand) i.e., how do we want to aggregate treatment effects across time/units
	- 2. Estimate the target parameter using only "clean-comparisons"

• Define  $ATT(q, t)$  to be ATT in period t for units first treated at period q,

$$
ATT(g, t) = E[Y_{it}(g) - Y_{it}(\infty)|G_i = g]
$$

• Define  $ATT(q, t)$  to be ATT in period t for units first treated at period q.

$$
ATT(g, t) = E[Y_{it}(g) - Y_{it}(\infty) | G_i = g]
$$

• Under PT and No Anticipation,  $ATT(q, t)$  is identified as

$$
ATT(g,t) = \underbrace{E[Y_{it} - Y_{i,g-1}|G_i = g]}_{\text{Change for cohort g}} - \underbrace{E[Y_{it} - Y_{i,g-1}|G_i = \infty]}_{\text{Change for never-treated units}}
$$

• Why?

• Define  $ATT(q, t)$  to be ATT in period t for units first treated at period q.

$$
ATT(g, t) = E[Y_{it}(g) - Y_{it}(\infty) | G_i = g]
$$

• Under PT and No Anticipation,  $ATT(q, t)$  is identified as

$$
ATT(g, t) = \underbrace{E[Y_{it} - Y_{i,g-1}|G_i = g]}_{\text{Change for cohort g}} - \underbrace{E[Y_{it} - Y_{i,g-1}|G_i = \infty]}_{\text{Change for never-treated units}}
$$

• Why? This is a two-group two-period comparison, so the argument is the same as in the canonical case!

• Start with

$$
E[Y_{it} - Y_{i,g-1}|G_i = g] - E[Y_{it} - Y_{i,g-1}|G_i = \infty]
$$

• Start with

$$
E[Y_{it} - Y_{i,g-1} | G_i = g] - E[Y_{it} - Y_{i,g-1} | G_i = \infty]
$$

• Apply definition of POs to obtain:

$$
E[Y_{it}(g) - Y_{i,g-1}(g)|G_i = g] - E[Y_{ig}(\infty) - Y_{i,g-1}(\infty)|G_i = \infty]
$$

• Start with

$$
E[Y_{it} - Y_{i,g-1} | G_i = g] - E[Y_{it} - Y_{i,g-1} | G_i = \infty]
$$

• Apply definition of POs to obtain:

$$
E[Y_{it}(g) - Y_{i,g-1}(g)|G_i = g] - E[Y_{ig}(\infty) - Y_{i,g-1}(\infty)|G_i = \infty]
$$

• Use No Anticipation to substitute  $Y_{i,q-1}(\infty)$  for  $Y_{i,q-1}(q)$ :

$$
E[Y_{it}(g) - Y_{i,g-1}(\infty)|G_i = g] - E[Y_{ig}(\infty) - Y_{i,g-1}(\infty)|G_i = \infty]
$$

**Start with** 

$$
E[Y_{it} - Y_{i,g-1} | G_i = g] - E[Y_{it} - Y_{i,g-1} | G_i = \infty]
$$

• Apply definition of POs to obtain:

$$
E[Y_{it}(g) - Y_{i,g-1}(g)|G_i = g] - E[Y_{ig}(\infty) - Y_{i,g-1}(\infty)|G_i = \infty]
$$

• Use No Anticipation to substitute  $Y_{i,q-1}(\infty)$  for  $Y_{i,q-1}(q)$ :

$$
E[Y_{it}(g) - Y_{i,g-1}(\infty)|G_i = g] - E[Y_{ig}(\infty) - Y_{i,g-1}(\infty)|G_i = \infty]
$$

• Add and subtract  $E[Y_{it}(\infty)|G_i = q]$  to obtain:

 $E[Y_{it}(q) - Y_{it}(\infty)|G_i = q] +$  $[E[Y_{it}(\infty) - Y_{i,a-1}(\infty) | G_i = g] - E[Y_{ia}(\infty) - Y_{i,a-1}(\infty) | G_i = \infty]]$ 

**Start with** 

$$
E[Y_{it} - Y_{i,g-1} | G_i = g] - E[Y_{it} - Y_{i,g-1} | G_i = \infty]
$$

• Apply definition of POs to obtain:

$$
E[Y_{it}(g) - Y_{i,g-1}(g)|G_i = g] - E[Y_{ig}(\infty) - Y_{i,g-1}(\infty)|G_i = \infty]
$$

• Use No Anticipation to substitute  $Y_{i,q-1}(\infty)$  for  $Y_{i,q-1}(q)$ :

$$
E[Y_{it}(g) - Y_{i,g-1}(\infty)|G_i = g] - E[Y_{ig}(\infty) - Y_{i,g-1}(\infty)|G_i = \infty]
$$

Add and subtract  $E[Y_{it}(\infty)|G_i = g]$  to obtain:

 $E[Y_{it}(q) - Y_{it}(\infty)|G_i = q] +$  $[E[Y_{it}(\infty) - Y_{i,a-1}(\infty) | G_i = q] - E[Y_{ia}(\infty) - Y_{i,a-1}(\infty) | G_i = \infty]]$ 

Cancel the last term using PT to get  $E[Y_{it}(g) - Y_{it}(\infty)|G_i = g] = ATT(g,t)$ 

• Define  $ATT(q, t)$  to be ATT in period t for units first treated at period q,

$$
ATT(g, t) = E[Y_{it}(g) - Y_{it}(\infty)|G_i = g]
$$

• Define  $ATT(q, t)$  to be ATT in period t for units first treated at period q,

$$
ATT(g, t) = E[Y_{it}(g) - Y_{it}(\infty)|G_i = g]
$$

• Under PT and No Anticipation,

$$
ATT(g, t) = \underbrace{E[Y_{it} - Y_{i,g-1}|G_i = g]}_{\text{Change for cohort g}} - \underbrace{E[Y_{it} - Y_{i,g-1}|G_i = \infty]}_{\text{Change for never-treated}}
$$

• Define  $ATT(q, t)$  to be ATT in period t for units first treated at period q.

$$
ATT(g, t) = E[Y_{it}(g) - Y_{it}(\infty)|G_i = g]
$$

• Under PT and No Anticipation,

$$
ATT(g, t) = \underbrace{E[Y_{it} - Y_{i,g-1}|G_i = g]}_{\text{Change for cohort g}} - \underbrace{E[Y_{it} - Y_{i,g-1}|G_i = \infty]}_{\text{Change for never-treated}}
$$

• We can then estimate this with sample analogs:

$$
\widehat{ATT}(g,t) = \underbrace{\widehat{E}[Y_{it} - Y_{i,g-1}|G_i = g]}_{\text{Sample change for cohort g}} - \underbrace{\widehat{E}[Y_{it} - Y_{i,g-1}|G_i = \infty]}_{\text{Sample change for never-treated}}
$$
\nwhere  $\widehat{E}$  denotes sample means.

- If have a large number of observations and relatively few groups/periods, can report  $\widehat{ATT}(q, t)$ 's directly.
- If there are many groups/periods, the  $\widehat{ATT}(q, t)$  may be very imprecisely estimated and/or too numerous to report concisely

• In these cases, it is often desirable to report sensible averages of the  $\widehat{ATT}(g, t)$ 's.

- In these cases, it is often desirable to report sensible averages of the  $\widehat{ATT}(a, t)$ 's.
- One of the most useful is to report event-study parameters which aggregate  $\widehat{ATT}(a, t)$ 's at a particular lag since treatment
	- $\to\,$  E.g.  $\hat{\theta}_k=\sum_g \widehat{ATT}(g,t+k)$  aggregates effects for cohorts in the  $k$ th period after treatment
	- $\rightarrow$  Can also construct for  $k < 0$  to estimate "pre-trends"

- In these cases, it is often desirable to report sensible averages of the  $\widehat{ATT}(a, t)$ 's.
- One of the most useful is to report event-study parameters which aggregate  $\widehat{ATT}(q, t)$ 's at a particular lag since treatment
	- $\to\,$  E.g.  $\hat{\theta}_k=\sum_g \widehat{ATT}(g,t+k)$  aggregates effects for cohorts in the  $k$ th period after treatment
	- $\rightarrow$  Can also construct for  $k < 0$  to estimate "pre-trends"
- C&S discuss other sensible aggregations too  $-$  e.g., if interested in whether treatment effects differ across good/bad economies, may want to "calendar averages" that pool the  $\widehat{ATT}(t, q)$  for the same year

# Comparisons of new estimators

- Callaway and Sant'Anna also propose an analogous estimator using *not-yet-treated* units as the control rather than never-treated units. This is generally more efficient.
- [Sun and Abraham \(2021\)](#page-36-0) propose a similar estimator but with different comparisons groups (e.g. using last-to-be treated rather than not-yet-treated)
- [Borusyak et al. \(2024\)](#page-36-1), [Wooldridge \(2021\)](#page-36-2), [Gardner \(2021\)](#page-36-3) propose "imputation" estimators that estimate the counterfactual  $\hat{Y}_{it}(0)$  using a TWFE model that is fit using only pre-treatment data:  $Y_{it}(0) = \lambda_t + \gamma_i + \epsilon_{it}$ 
	- $\rightarrow$  Main difference from C&S is that this uses more pre-treatment periods, not just period  $q 1$
	- $\rightarrow$  This can sometimes be more efficient (if outcome not too serially correlated), but also relies on a stronger PT assumption that may be more susceptible to bias
- [Roth and Sant'Anna \(2023\)](#page-36-4) show that you can get even more precise estimates if you're willing to assume treatment timing is "as good as random"

• Don't freak out about this new literature!

- Don't freak out about this new literature!
- In most cases, using the "new" DiD methods will not lead to a big change in your results (empirically, TE heterogeneity is not *that* large in most cases)
	- $\rightarrow$  The exceptions are cases where there are periods where almost all units are treated this is when "forbidden comparisons" get the most weight

- Don't freak out about this new literature!
- In most cases, using the "new" DiD methods will not lead to a big change in your results (empirically, TE heterogeneity is not *that* large in most cases)
	- $\rightarrow$  The exceptions are cases where there are periods where almost all units are treated this is when "forbidden comparisons" get the most weight
- The most important thing is to be precise about who you want the comparison group to be and to choose a method that only uses these "clean comparisons"

- Don't freak out about this new literature!
- In most cases, using the "new" DiD methods will not lead to a big change in your results (empirically, TE heterogeneity is not *that* large in most cases)
	- $\rightarrow$  The exceptions are cases where there are periods where almost all units are treated this is when "forbidden comparisons" get the most weight
- The most important thing is to be precise about who you want the comparison group to be and to choose a method that only uses these "clean comparisons"
- In my experience, the difference between the new estimators is typically not that large  $$ can report multiple new methods for robustness (to make your referees happy!) although in my view this is not strictly necessary

#### References I

<span id="page-36-1"></span>**Borusyak, Kirill, Xavier Jaravel, and Jann Spiess**, "Revisiting Event-Study Designs: Robust and Efficient Estimation," *The Review of Economic Studies*, November 2024, *91* (6), 3253–3285.

<span id="page-36-3"></span>**Gardner, John**, "Two-stage differences in differences," *Working Paper*, 2021.

- <span id="page-36-4"></span>**Roth, Jonathan and Pedro H. C. Sant'Anna**, "Efficient Estimation for Staggered Rollout Designs," *Journal of Political Economy Microeconomics*, November 2023, *1* (4), 669–709. Publisher: The University of Chicago Press.
- <span id="page-36-0"></span>**Sun, Liyang and Sarah Abraham**, "Estimating dynamic treatment effects in event studies with heterogeneous treatment effects," *Journal of Econometrics*, 2021, *225* (2), 175–199.

<span id="page-36-2"></span>**Wooldridge, Jeffrey M**, "Two-Way Fixed Effects, the Two-Way Mundlak Regression, and Difference-in-Differences Estimators," *Working Paper*, 2021, pp. 1–89.